HOME > BUSINESS > Article

Text Size

small

medium

large


Eisai, Biogen Seek U.S. Approval for Potential Alzheimer's Drug

Eisai, Biogen Seek U.S. Approval for Potential Alzheimer's Drug

   Tokyo, July 9 (Jiji Press)--Eisai Co. <4523> has announced that an application has been completed to gain approval from the U.S. Food and Drug Administration for aducanumab, a potential Alzheimer's drug jointly developed by the Japanese drugmaker and major U.S. biopharmaceutical firm Biogen.
   "If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease," the two companies said in a statement Wednesday.

To read a full story, please click here to find out how to subscribe.

BUSINESS

Aomori Tourism Information

HEADLINES

POLITICS
Japan Cautious about Importing Russia's Coronavirus Vaccine: Health Min. Kato
ECONOMY
Japan Govt Approves 1st Batch of Cultural Tourism Programs Involving 10 Areas
SPORTS
J. League Soccer: Up to Sagan Tosu Players, Staff Members May Have Coronavirus
OTHER
6,664 People Ambulanced for Heat Stroke across Japan in Week through Sun.

AFP-JIJI PRESS NEWS JOURNAL


Photos